Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 12.6 SEK 1.12%
Market Cap: 3.5B SEK

Wall Street
Price Targets

VICO Price Targets Summary
Vicore Pharma Holding AB

Wall Street analysts forecast VICO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VICO is 24.48 SEK with a low forecast of 15.15 SEK and a high forecast of 42 SEK.

Lowest
Price Target
15.15 SEK
20% Upside
Average
Price Target
24.48 SEK
94% Upside
Highest
Price Target
42 SEK
233% Upside
Vicore Pharma Holding AB Competitors:
Price Targets
ATRA
Atara Biotherapeutics Inc
47% Upside
2171
CARsgen Therapeutics Holdings Ltd
43% Upside
1530
3SBio Inc
42% Upside
REGN
Regeneron Pharmaceuticals Inc
1% Upside
RXRX
Recursion Pharmaceuticals Inc
53% Upside
TNG
Transgene SA
50% Upside
BMRN
Biomarin Pharmaceutical Inc
56% Upside
688331
RemeGen Co Ltd
2% Downside

Revenue
Forecast

Revenue Estimate
Vicore Pharma Holding AB

For the last 13 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 34%. The projected CAGR for the next 4 years is -45%.

34%
Past Growth
-45%
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VICO's stock price target?
Price Target
24.48 SEK

According to Wall Street analysts, the average 1-year price target for VICO is 24.48 SEK with a low forecast of 15.15 SEK and a high forecast of 42 SEK.

What is Vicore Pharma Holding AB's Revenue forecast?
Projected CAGR
-45%

For the last 13 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 34%. The projected CAGR for the next 4 years is -45%.

Back to Top